首页> 美国卫生研究院文献>PLoS Pathogens >Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide
【2h】

Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide

机译:表达人牛磺胆酸钠共转运多肽的小鼠的D型肝炎病毒感染

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatitis D virus (HDV) is the smallest virus known to infect human. About 15 million people worldwide are infected by HDV among those 240 million infected by its helper hepatitis B virus (HBV). Viral hepatitis D is considered as one of the most severe forms of human viral hepatitis. No specific antivirals are currently available to treat HDV infection and antivirals against HBV do not ameliorate hepatitis D. Liver sodium taurocholate co-transporting polypeptide (NTCP) was recently identified as a common entry receptor for HDV and HBV in cell cultures. Here we show HDV can infect mice expressing human NTCP (hNTCP-Tg). Antibodies against critical regions of HBV envelope proteins blocked HDV infection in the hNTCP-Tg mice. The infection was acute yet HDV genome replication occurred efficiently, evident by the presence of antigenome RNA and edited RNA species specifying large delta antigen in the livers of infected mice. The resolution of HDV infection appears not dependent on adaptive immune response, but might be facilitated by innate immunity. Liver RNA-seq analyses of HDV infected hNTCP-Tg and type I interferon receptor 1 (IFNα/βR1) null hNTCP-Tg mice indicated that in addition to induction of type I IFN response, HDV infection was also associated with up-regulation of novel cellular genes that may modulate HDV infection. Our work has thus proved the concept that NTCP is a functional receptor for HDV infection in vivo and established a convenient small animal model for investigation of HDV pathogenesis and evaluation of antiviral therapeutics against the early steps of infection for this important human pathogen.
机译:丁型肝炎病毒(HDV)是已知感染人类的​​最小的病毒。全球约有1500万人受到HDV感染,其中有2.4亿人受到其辅助性乙型肝炎病毒(HBV)感染。丙型病毒性肝炎被认为是人类病毒性肝炎最严重的形式之一。目前尚无可用于治疗HDV感染的特异性抗病毒药,抗HBV的抗病毒药也不能改善D型肝炎。牛磺胆酸钠共转运多肽(NTCP)最近被确定为细胞培养物中HDV和HBV的常见进入受体。在这里,我们显示HDV可以感染表达人NTCP(hNTCP-Tg)的小鼠。针对HBV包膜蛋白关键区域的抗体可阻断hNTCP-Tg小鼠的HDV感染。感染是急性的,但HDV基因组复制有效地发生,这由反基因组RNA的存在和编辑的RNA种类所证实,表明感染的小鼠肝脏中存在较大的δ抗原。 HDV感染的解决方法似乎并不依赖于适应性免疫反应,但先天免疫可能会促进这种情况。 HDV感染的hNTCP-Tg和I型干扰素受体1(IFNα/βR1)无效的hNTCP-Tg小鼠的肝RNA序列分析表明,除了诱导I型IFN反应外,HDV感染还与新型Ig干扰素的上调有关可能调节HDV感染的细胞基因。因此,我们的工作证明了NTCP是体内HDV感染的功能性受体的概念,并建立了一个方便的小动物模型,用于研究HDV的发病机理和评估针对该重要人类病原体的早期感染的抗病毒治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号